Skip to main content

PADCEV (Astellas Pharma Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
240 (255 working days)
Active ingredients
enfortumab vedotin
Registration type

PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Help us improve the Therapeutic Goods Administration site